Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive in Vancouver to discuss the major announcement from the company that they have received their key Heath Canada Licence that allows them Processing & Sales for Medical Purposes.
Goldstein also discussed how much money they were able to raise and why a certain consultant with the company will be key to their success going forward.
CSE:PILL
Market: CSE
Market Cap: $13.67 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: Canntab Therapeutics granted cannabis research licence from...
Canntab Therapeutics Limited (CSE:PILL-OTCQB: CTABF) Co-Founder and CFO Richard Goldstein joined Steve Darling from Proactive Vancouver on Skype to discuss the company being granted their cannabis research license from Health Canada. Goldstein talks about what this license allows Canntab to do...
1 week, 1 day ago
2 min read
Prev article
2 min read
